The Effect of Probiotic and/or Prebiotic on Liver Function Tests in Patients with Nonalcoholic Fatty Liver Disease: A Double Blind Randomized Clinical Trial

被引:40
作者
Javadi, Leila [1 ]
Ghavami, Mostafa [2 ]
Khoshbaten, Manouchehr [3 ]
Safaiyan, Abdolrasoul [4 ]
Barzegari, Abolfazl [5 ]
Gargari, Bahram Pourghassem [6 ]
机构
[1] Tabriz Univ Med Sci, Nutr Res Ctr, Student Res Comm, Tabriz, Iran
[2] Tabriz Univ Med Sci, Fac Paramed, Tabriz, Iran
[3] Tabriz Univ Med Sci, Liver & Gastrointestinal Dis Res Ctr, Tabriz, Iran
[4] Rd Traff Injury Res Ctr, Dept Biostat & Epidemiol, Tabriz, Iran
[5] Tabriz Univ Med Sci, Res Ctr Pharmaceut Nanotechnol, Tabriz, Iran
[6] Tabriz Univ Med Sci, Sch Nutr & Food Sci, Dept Biochem & Diet Therapy, Nutr Res Ctr, Tabriz, Iran
关键词
Probiotic; Prebiotic; Liver Function; Steatosis; NAFLD; GUT MICROBIOTA; INSULIN-RESISTANCE; OBESITY; STEATOHEPATITIS; AMINOTRANSFERASES; ENDOTOXEMIA; MECHANISM; DIAGNOSIS; NAFLD; MICE;
D O I
10.5812/ircmj.46017
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Oral administration of pro-and prebiotics has recently been considered as an effective way for nonalcoholic fatty liver disease (NAFLD) recovery. Objectives: The current study aimed at evaluating the effect of supplementation with probiotics and/or prebiotics on liver function tests in patients with NAFLD. Methods: In this double blind, placebo-control clinical trial, 75 subjects with NAFLD were voluntarily recruited from May 2013 to March 2014, in Iran. Participants were randomly assigned to 1 of 4 groups using a block randomization procedure. Group 1 received probiotic capsules (Bifidobacterium longum (BL) and Lactobacillus acidophilus (LA): 2 x 10(7) CFU/day), group 2 received prebiotic inulin high performance (HP): 10 g/day, group 3 received probiotic and the prebiotic, and group 4 received a placebo for 3 months. The sample size was determined on the basis of a primary outcome of a change in aspartate aminotransferase (AST) level. Results: Anintergroup comparison indicated that the AST (P =0.006) and alanine aminotransferase (ALT) (P = 0.04) levels decreased at the end of the study. Aspartate Aminotransferase (mean difference of group1 versus placebo with P value of 0.001, group2 versus placebo with P value of 0.045, group3 versus placebo with P value of 0.015) and ALT (mean difference of group 1 versus placebo with P value of 0.009, group 2 versus placebo with P value of 0.041, and group 3 versus placebo with P value of 0.046) serum levels decreased significantly in all of the intervention groups compared to the placebo. The grade of fatty liver in group 1 (P of 0.027, and number needed to treat (NNT) = 3) and group 3 (P = 0.019 and NNT = 3) decreased compared to the placebo group with no significant changes in group 2. Conclusions: Supplementation with probiotics and/or prebiotics improved aminotransferase enzymes,and supplementation with probiotics or pro-and prebiotics recovered the grade of fatty liver in NAFLD patients.
引用
收藏
页数:9
相关论文
共 50 条
  • [31] A clinical model to predict fibrosis on liver biopsy in paediatric subjects with nonalcoholic fatty liver disease
    Kulkarni, Sakil
    Naz, Nadia
    Gu, Hongjie
    Stoll, Janis M.
    Thompson, Michael D.
    DeBosch, Brian J.
    CLINICAL OBESITY, 2021, 11 (05)
  • [32] Effect of a Probiotic and Metformin on Liver Aminotransferases in Non-alcoholic Steatohepatitis: A Double Blind Randomized Clinical Trial
    Shavakhi, Ahmad
    Minakari, Mohammad
    Firouzian, Hassan
    Assali, Raheleh
    Hekmatdoost, Azita
    Ferns, Gordon
    INTERNATIONAL JOURNAL OF PREVENTIVE MEDICINE, 2013, 4 (05) : 531 - 537
  • [33] Effect of Probiotics Therapy on Nonalcoholic Fatty Liver Disease
    Huang, Yuanshe
    Wang, Xiaodong
    Zhang, Lai
    Zheng, Ke
    Xiong, Jie
    Li, Jing
    Cong, Chunlei
    Gong, Zhaomiao
    Mao, Jingxin
    COMPUTATIONAL AND MATHEMATICAL METHODS IN MEDICINE, 2022, 2022
  • [34] Combined Amelioration of Prebiotic Resveratrol and Probiotic Bifidobacteria on Obesity and Nonalcoholic Fatty Liver Disease
    Hu, Danhong
    Yang, Wenjuan
    Mao, Peijiang
    Cheng, Minyu
    NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL, 2021, 73 (04): : 652 - 661
  • [35] Obesity and Weight Gain Are Associated With Progression of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease
    Kim, Yejin
    Chang, Yoosoo
    Cho, Yong Kyun
    Ahn, Jiin
    Shin, Hocheol
    Ryu, Seungho
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2019, 17 (03) : 543 - +
  • [36] The Effect of Alpha-Lipoic Acid on Liver Function and Metabolic Markers in Obese Patients with Non-Alcoholic Fatty Liver Disease: A Double - Blind Randomized Controlled Trial
    Amirkhizi, Farshad
    Hamedi-Shahraki, Soudabeh
    Hosseinpour-Arjmand, Sonya
    Ebrahimi-Mameghani, Mehrangiz
    IRANIAN RED CRESCENT MEDICAL JOURNAL, 2018, 20 (03)
  • [37] Treatment options for nonalcoholic fatty liver disease: a double-blinded randomized placebo-controlled trial
    Anushiravani, Amir
    Haddadi, Niloufar
    Pourfarmanbar, Maedeh
    Mohammadkarimi, Vahid
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2019, 31 (05) : 613 - 617
  • [38] Effects of dapagliflozin on liver steatosis in patients with nonalcoholic fatty liver disease: a randomized controlled trial
    Weng, Meng-Tzu
    Yang, Po-Jen
    Liu, Pan-Fu
    Chang, Chin-Hao
    Lee, Hsuan-Shu
    Sheu, Jin-Chuan
    Nien, Hsiao-Ching
    HEPATOLOGY INTERNATIONAL, 2024, : 405 - 414
  • [39] Hyperferritinemia in patients with nonalcoholic fatty liver disease
    Barros, Raffaelle K.
    Cotrim, Helma Pinchemel
    Daltro, Carla H.
    Oliveira, Yanaihara A.
    REVISTA DA ASSOCIACAO MEDICA BRASILEIRA, 2017, 63 (03): : 284 - 289
  • [40] Adiponectin is better predictor of subclinical atherosclerosis than liver function tests in patients with nonalcoholic fatty liver disease
    Omelchenko, Elena
    Gavish, Dov
    Shargorodsky, Marina
    JOURNAL OF THE AMERICAN SOCIETY OF HYPERTENSION, 2014, 8 (06) : 376 - 380